Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Prepaid Assets (2021 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Prepaid Assets for 5 consecutive years, with $6.2 million as the latest value for Q4 2025.

  • Quarterly Prepaid Assets fell 10.05% to $6.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.2 million through Dec 2025, down 10.05% year-over-year, with the annual reading at $6.2 million for FY2025, 10.05% down from the prior year.
  • Prepaid Assets hit $6.2 million in Q4 2025 for ARS Pharmaceuticals, down from $6.4 million in the prior quarter.
  • In the past five years, Prepaid Assets ranged from a high of $11.6 million in Q1 2025 to a low of $137000.0 in Q3 2024.
  • Historically, Prepaid Assets has averaged $3.7 million across 5 years, with a median of $3.4 million in 2021.
  • Biggest five-year swings in Prepaid Assets: tumbled 94.66% in 2024 and later skyrocketed 4586.86% in 2025.
  • Year by year, Prepaid Assets stood at $667000.0 in 2021, then surged by 397.6% to $3.3 million in 2022, then rose by 1.42% to $3.4 million in 2023, then soared by 104.58% to $6.9 million in 2024, then decreased by 10.05% to $6.2 million in 2025.
  • Business Quant data shows Prepaid Assets for SPRY at $6.2 million in Q4 2025, $6.4 million in Q3 2025, and $1.0 million in Q2 2025.